Patent · US Expired

Substituted imidazole derivatives

US7576221B2 · kind B2 · utility

3Cited by

5References

18Claims

0Family size

Assignee

Novartis Vaccines and Diagnostics, Inc. · US

Inventors

Weibo Wang · Moraga, US
Paul A. Barsanti · Emeryville, US
Yia Xia · Palo Alto, US
Rustum Boyce · San Francisco, US
Sabina Pecchi · Oakland, US
Nathan Brammeier · Walnut Creek, US
Megan C. Phillips · Lake Orion, US
Kris Mendenhall · Concord, US
Kelly Wayman · San Rafael, US
Liana Lagniton · Berkeley, US
Ryan Constantine · Oakland, US
Hong Yang · Foster City, US
Elizabeth Mieuli · Redwood City, US
Savithri Ramurthy · Walnut Creek, US
Elisa Jazan · Richmond, US
Anu Sharma · Corona, US
Rama Jain · Danville, US
Sharadha Subramanian · San Ramon, US
Paul A. Renhowe · Danville, US
Kenneth W. Bair · Chapel Hill, US
David Duhl · Newington, US
Annette Walter · Mill Valley, US
Tinya Abrams · Richmond, US
Kay Huh · San Mateo, US
Eric Martin · Corona, US
Mark Knapp · Oakland, US
Vincent P. Le · San Francisco, US

Key dates

Filing date	Jun 20, 2005
Grant date	Aug 18, 2009
Priority date	—
Expiry date	Nov 8, 2025

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/10
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.